tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NAMS Stock Latest News

NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
The FlyNewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
9d ago
NAMS
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
16d ago
CYTK
MNPR
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
PremiumRatings
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
16d ago
NAMS
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
PremiumRatings
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
21d ago
NAMS
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
PremiumRatings
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
21d ago
NAMS
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
PremiumCompany AnnouncementsNewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
21d ago
8K
NAMS
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
Premium
The Fly
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
21d ago
NAMS
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
Premium
The Fly
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
2M ago
NAMS
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
PremiumRatings
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
3M ago
NAMS
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
PremiumRatings
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
3M ago
NAMS
NewAmsterdam Pharma Reports Q3 2025 Financial Results
PremiumCompany Announcements
NewAmsterdam Pharma Reports Q3 2025 Financial Results
3M ago
NAMS
Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments
PremiumRatings
Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments
3M ago
NAMS
NewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating
PremiumRatingsNewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating
3M ago
NAMS
Optimistic Buy Rating for NewAmsterdam Pharma: Strong Financials, Promising R&D, and Strategic Growth Initiatives
Premium
Ratings
Optimistic Buy Rating for NewAmsterdam Pharma: Strong Financials, Promising R&D, and Strategic Growth Initiatives
3M ago
NAMS
NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone
Premium
Company Announcements
NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone
3M ago
8K
NAMS
NewAmsterdam Pharma reports Q3 revenue $348,000, consensus $4.56M
PremiumThe Fly
NewAmsterdam Pharma reports Q3 revenue $348,000, consensus $4.56M
3M ago
NAMS
NewAmsterdam Pharma’s Latest Study: A Game Changer for Metabolic Disorders?
PremiumCompany Announcements
NewAmsterdam Pharma’s Latest Study: A Game Changer for Metabolic Disorders?
3M ago
NAMS
NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?
PremiumCompany Announcements
NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?
3M ago
NAMS
NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment
PremiumCompany Announcements
NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment
3M ago
NAMS
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment
PremiumCompany AnnouncementsNewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment
3M ago
NAMS
Analyst Recommends Buy on NewAmsterdam Pharma for Promising CETPi Obicetrapib
Premium
Ratings
Analyst Recommends Buy on NewAmsterdam Pharma for Promising CETPi Obicetrapib
3M ago
NAMS
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright
Premium
The Fly
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright
3M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >